Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Rystiggo Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.648

    Clinical Policy: Rozanolixizumab-noli (Rystiggo)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.648 alerts

    Get alerted when Policy CP.PHAR.648 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Rystiggo in adults with anti-AChR- or anti-MuSK-positive generalized myasthenia gravis across commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerAmbetter Nevada
    PolicyRozanolixizumab-noli (Rystiggo) coverage
    Policy CodePolicy CP.PHAR.648
    Change TypeModified
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit office chart notes, laboratory results, or other clinical information supporting that the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The 2024 annual revision added the 420 mg/3 mL, 560 mg/4 mL, and 840 mg/6 mL formulations, updated quantity limits to one vial, and added Bkemv, Epysqli, and Zilbrysq to therapies that should not be prescribed concurrently with Rystiggo.

    The 2025 annual revision clarified that required immunosuppressive therapy for generalized myasthenia gravis must be non-steroidal and extended Medicaid and HIM approval durations from 6 to 12 months.

    The 2026 annual revision added Imaavy and Uplizna to the therapies that should not be prescribed concurrently with Rystiggo and added the ICHRA line of business.

    ≥3Baseline MG-ADL
    II–IVaMGFA classification
    2-point reduction

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continuation response
    6 weeksInitial dosing cycle
    840 mg/weekMaximum dose
    2HCPCS codes

    Coverage Criteria

    Initial Therapy

    Coverage requires ALL of the following criteria for initial therapy in generalized myasthenia gravis.

    ALL of the following

    • Diagnosis of generalized myasthenia gravis (gMG).
    • Prescribed by or in consultation with a neurologist.
    • Member is age 18 years or older.>= 18 years
    • Myasthenia Gravis-Activities of Daily Living (MGADL) score is at least 3 from non-ocular symptoms at baseline.>= 3
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification is Class II to IVa.
    • ONE of the following serologic tests is positive

      • Anti-AChR antibodies.
      • Anti-MuSK antibodies.
    • If the member has positive anti-AChR antibodies, failure of a cholinesterase inhibitor, unless contraindicated or clinically significant adverse effects are experienced.

      For Illinois HIM requests, the step-therapy requirement does not apply as of 1/1/2026 per IL HB 5395.

    • Failure of a corticosteroid, unless contraindicated or clinically significant adverse effects are experienced.

      For Illinois HIM requests, the step-therapy requirement does not apply as of 1/1/2026 per IL HB 5395.

    • Failure of at least one non-steroidal immunosuppressive therapy, unless clinically significant adverse effects are experienced or all are contraindicated.

      For Illinois HIM requests, the step-therapy requirement does not apply as of 1/1/2026 per IL HB 5395.

    • Documentation of the member's current weight in kilograms.
      • Weight-based dose

        • Weight less than 50 kg: 420 mg.
        • Weight 50 kg to less than 100 kg: 560 mg.
        • Weight 100 kg or greater: 840 mg.
      • No more than 1 vial.

    Continuation Therapy

    Coverage requires ALL of the following criteria for continuation therapy in generalized myasthenia gravis.

    ALL of the following

    • ONE of the following

      • Member is currently receiving the medication through the Centene benefit or previously met initial approval criteria.
      • Member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations; refer to state-specific addenda CC.PHARM.03A and CC.PHARM.03B.
    • Member is responding positively to therapy, evidenced by a 2-point reduction in total MG-ADL score from baseline.2-point reduction
    • Documentation of the member's current weight in kilograms.

    Other Diagnoses and Indications

    For other diagnoses or indications, route the request according to the applicable line of business and the following criteria.

    ONE of the following

      • Use the applicable policy

        • If the drug is on the formulary or PDL, use the no-coverage-criteria policy: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • If the drug is not on the formulary or PDL, use the non-formulary policy: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • The requested use, including diagnosis, age, or dosing regimen, is not specifically listed under Section III and the label-change criterion above does not apply.

      Refer to the applicable off-label use policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety is provided under the applicable off-label use policy—CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid—or under applicable evidence of coverage documents.

    Rystiggo must not be prescribed concurrently with Imaavy, Vyvgart, Vyvgart Hytrulo, Soliris, Bkemv, Epysqli, Ultomiris, Uplizna, or Zilbrysq. This concurrent-use exclusion applies to both initial and continuation therapy.

    Coding and Clinical Parameters

    HCPCS CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    Baseline MG-ADL
    Required baseline scoreMG-ADL ≥ 3
    Symptoms countedNon-ocular symptoms
    TimingAt baseline
    MGFA Classification
    Required rangeMGFA Class II to IVa
    Classification basisExtent and severity of muscle weakness
    Class IVa patternPredominantly limb and/or axial muscle impairment

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit clinical documentation supporting that the member meets all applicable approval criteria before Rystiggo can be authorized.

    • Include documentation supporting each applicable initial or continuation criterion.
    • Submit office chart notes, laboratory results, and other relevant clinical information.
    Step Therapy

    Required Prior Therapies

    Document required prior therapy before requesting initial approval. Step-therapy requirements may be bypassed when the applicable exception is met.

    • For anti-AChR-positive members: failure of a cholinesterase inhibitor, unless contraindicated or clinically significant adverse effects occurred.
    • Failure of a corticosteroid, unless contraindicated or clinically significant adverse effects occurred.
    • Failure of at least one non-steroidal immunosuppressive therapy, unless clinically significant adverse effects occurred or all such therapies are contraindicated.

    Clinical Background

    Rozanolixizumab-noli (Rystiggo) is a neonatal Fc receptor blocker indicated for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. The policy uses MG-ADL functional scoring and MGFA clinical classification to assess disease burden and response; a 2-point reduction in MG-ADL is considered a clinically meaningful response.

    Definitions and Abbreviations

    AChR
    AbbreviationAChR
    Full termAcetylcholine receptor
    Policy useAnti-AChR antibody positivity is one qualifying serologic pathway
    gMG
    AbbreviationgMG
    Full termGeneralized myasthenia gravis
    Policy populationAdults with gMG are evaluated for Rystiggo coverage under the policy criteria

    Initial Therapy

    Initial Therapy Criteria

    Initial approval requires all criteria below.

    Initial Rystiggo therapy

    • Clinical eligibility: Diagnosis of generalized myasthenia gravis; prescribed by or in consultation with a neurologist; age 18 years or older; baseline MG-ADL score of at least 3 from non-ocular symptoms; and MGFA clinical classification of Class II to IVa.Age ≥18 years; MG-ADL ≥3; MGFA Class II-IVa
    • Serologic positivity: Member has a positive serologic test for anti-AChR antibodies or anti-MuSK antibodies.At least one positive antibody test
    • Prior therapy requirements:

    Continued Therapy

    Continuation Criteria

    Continuation approval requires all criteria below.

    Continuation Rystiggo therapy

    • Eligibility for continuation: Member is currently receiving the medication through a Centene benefit or previously met initial approval criteria; or member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations.At least one eligibility pathway

      Refer to applicable state-specific continuity-of-care addenda when relevant.

    • Clinical response: Member is responding positively to therapy, demonstrated by a 2-point reduction in total MG-ADL score from baseline.MG-ADL reduction ≥2 points

    Required Prior Therapy

    StepApplies toRequired prior therapyException
    1Anti-AChR-antibody-positive membersCholinesterase inhibitorNot required if contraindicated or clinically significant adverse effects are experienced
    2All membersCorticosteroidNot required if contraindicated or clinically significant adverse effects are experienced
    3All membersAt least one non-steroidal immunosuppressive therapyNot required if clinically significant adverse effects are experienced or all such therapies are contraindicated

    Quantity and Dose Limits

    Rystiggo Quantity Limit
    Quantity limitOne vial per weekly dose
    Initial cycleFor the first 6 weeks
    Cycle intervalOf every 9-week cycle
    Rystiggo Maximum Dose
    Maximum dose840 mg/week
    IndicationGeneralized myasthenia gravis
    Dose basisMaximum dose listed in dosage and administration
    Policy Summary
    PayerAmbetter Nevada
    PolicyRozanolixizumab-noli (Rystiggo) coverage
    Policy CodePolicy CP.PHAR.648
    Change TypeModified
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit office chart notes, laboratory results, or other clinical information supporting that the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Requirements and Denial RisksClinical BackgroundDefinitions and AbbreviationsInitial TherapyContinued TherapyRequired Prior TherapyQuantity and Dose Limits
    • Weight-based dose

      • Weight less than 50 kg: 420 mg.
      • Weight 50 kg to less than 100 kg: 560 mg.
      • Weight 100 kg or greater: 840 mg.
    • No more than 1 vial.
  1. Weight-Based Weekly Dose
    Weight below 50 kg420 mg once weekly
    Weight 50 kg to less than 100 kg560 mg once weekly
    Weight at least 100 kg840 mg once weekly
    Continuation MG-ADL Response
    Required response2-point reduction in total MG-ADL score
    Comparison pointFrom baseline
    Clinical significanceA 2-point decrease is considered a clinically meaningful response
    Maximum Weekly Dose
    Maximum weekly dose840 mg/week
    IndicationGeneralized myasthenia gravis
    Administration frequencyOnce weekly during the initial dosing period
  2. The policy notes that Illinois HIM step-therapy requirements do not apply as of January 1, 2026, under IL HB 5395; this exception is not applicable to Ambetter Nevada requests.
  3. Documentation Required

    Clinical Documentation Required

    Provide supporting clinical information with the request so the plan can verify diagnosis, treatment history, severity, and dosing eligibility.

    • Office or specialist chart notes.
    • Relevant laboratory and serologic results.
    • MG-ADL assessment and MGFA classification.
    • Current weight in kilograms and the requested dose.
    Documentation Required

    Initial Clinical Criteria

    For initial generalized myasthenia gravis approval, document that the member meets all required clinical criteria.

    • Diagnosis of generalized myasthenia gravis (gMG).
    • Rystiggo is prescribed by or in consultation with a neurologist.
    • Age is ≥ 18 years.
    • Baseline MG-ADL total score is ≥ 3 from non-ocular symptoms.
    • MGFA clinical classification is Class II, III, or IVa.
    • Positive serologic test for anti-AChR or anti-MuSK antibodies.
    • If anti-AChR antibody positive, failure of a cholinesterase inhibitor unless contraindicated or clinically significant adverse effects occurred.
    • Failure of a corticosteroid unless contraindicated or clinically significant adverse effects occurred.
    • Failure of at least one non-steroidal immunosuppressive therapy unless clinically significant adverse effects occurred or all are contraindicated.
    Step Therapy

    Prior-Treatment History

    Document the member’s treatment history for each required prior therapy. The record must show failure, a qualifying contraindication, or clinically significant adverse effects as specified by the policy.

    • Cholinesterase inhibitor failure is required for anti-AChR-positive members unless contraindicated or associated with clinically significant adverse effects.
    • Corticosteroid failure is required unless contraindicated or associated with clinically significant adverse effects.
    • At least one non-steroidal immunosuppressive therapy must have failed, unless clinically significant adverse effects occurred or all available therapies are contraindicated.
    • Potential alternatives include pyridostigmine or neostigmine; corticosteroids such as prednisone, methylprednisolone, dexamethasone, or betamethasone; and non-steroidal immunosuppressants such as azathioprine, mycophenolate mofetil, cyclosporine, or rituximab products.
    Billing Rule

    Weight and Dose Documentation

    Include the member’s current weight in kilograms and document the requested Rystiggo dose. The dose must be administered once weekly for the first 6 weeks of each 9-week cycle and must remain within the applicable weight-based and quantity limits.

    • Weight < 50 kg: maximum 420 mg once weekly.
    • Weight 50 kg to < 100 kg: maximum 560 mg once weekly.
    • Weight ≥ 100 kg: maximum 840 mg once weekly.
    • The dose may not exceed 1 vial per administration.
    • For gMG, the maximum dose is 840 mg per week.

    Unsupported block type: documentation

    Denial Risk

    Initial Criteria Not Met

    Initial approval may be denied when the member does not satisfy the required gMG criteria. Submit documentation addressing every criterion before requesting authorization.

    • No documented gMG diagnosis.
    • No neurologist prescription or consultation.
    • Age under 18 years.
    • Baseline MG-ADL score below 3 from non-ocular symptoms.
    • MGFA classification outside Class II to IVa.
    • No positive anti-AChR or anti-MuSK serologic test.
    • Required prior therapies have not failed and no qualifying exception is documented.
    Denial Risk

    Concurrent Prohibited Therapy

    Rystiggo must not be prescribed concurrently with excluded therapies. Requests may be denied when concurrent use is documented or not adequately addressed.

    • Imaavy.
    • Vyvgart or Vyvgart Hytrulo.
    • Soliris, Bkemv, or Epysqli.
    • Ultomiris.
    • Uplizna.
    • Zilbrysq.
    Denial Risk

    Dose or Quantity Exceeds Limit

    Requests may be denied when the documented or requested dose exceeds the applicable weight-based limit, exceeds 1 vial, or exceeds the overall maximum of 840 mg per week.

    • Verify current weight in kilograms before selecting the dose.
    • Apply the 420 mg, 560 mg, or 840 mg weekly limit based on weight.
    • Limit administration to 1 vial once weekly for the first 6 weeks of every 9-week cycle.
    • For dose increases, document the new dose and confirm that it remains within all limits.
    Denial Risk

    Continuation Response Not Demonstrated

    Continuation requests may be denied when eligibility through prior approval or continuity of care is not established, or when the required clinical response is not demonstrated.

    • Document current Centene-benefit coverage, prior satisfaction of initial criteria, or applicable continuity-of-care eligibility.
    • Document a ≥ 2-point reduction in MG-ADL total score from baseline.
    • A current MG-ADL assessment without the baseline comparison may be insufficient.
    Denial Risk

    Non-FDA-Approved Use

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient efficacy and safety documentation supports review under the applicable off-label use policy.

    • Commercial: CP.CPA.09.
    • Health insurance marketplace/ICHRA: HIM.PA.154.
    • Medicaid: CP.PMN.53.
    • Submit evidence of efficacy and safety when routing an otherwise unaddressed off-label use under the applicable policy or evidence of coverage documents.
    MG-ADL
    Full termMyasthenia Gravis-Activities of Daily Living
    FormatEight-item patient-reported scale
    PurposeMeasures functional impairment related to myasthenia gravis
    MGFA
    AbbreviationMGFA
    Full termMyasthenia Gravis Foundation of America
    PurposeClinical classification of disease severity
    MuSK
    AbbreviationMuSK
    Full termMuscle-specific tyrosine kinase
    Policy useAnti-MuSK antibody positivity is one qualifying serologic pathway
    MGFA Classification
    Classification basisStratifies patients by the extent and severity of muscle weakness
    Class IVaImpairment predominantly involves the limb and/or axial muscles
    Class IVb distinctionImpairment predominantly involves the oropharyngeal and/or respiratory muscles
    MG-ADL
    Scale structureEight-item patient-reported scale
    DomainsTalking, chewing, swallowing, breathing, brushing teeth or combing hair, arising from a chair, double vision, and eyelid droop
    ScoringEach domain is scored from 0 to 3; 0 is normal and 3 is the most severe impairment
    If anti-AChR antibody positive, failure of a cholinesterase inhibitor unless contraindicated or clinically significant adverse effects occurred; failure of a corticosteroid unless contraindicated or clinically significant adverse effects occurred; and failure of at least one non-steroidal immunosuppressive therapy unless clinically significant adverse effects occurred or all such therapies are contraindicated.
    Required treatment failures or qualifying exceptions
  4. Concurrent therapy exclusion: Rystiggo is not prescribed concurrently with Imaavy, Vyvgart, Vyvgart Hytrulo, Soliris, Bkemv, Epysqli, Ultomiris, Uplizna, or Zilbrysq.No concurrent listed therapy
  5. Dose and quantity: The member's current weight in kilograms is documented, and the dose does not exceed both the applicable weight-based dose and one vial once weekly for the first 6 weeks of every 9-week cycle.420 mg if weight <50 kg; 560 mg if weight 50 to <100 kg; 840 mg if weight ≥100 kg; maximum 1 vial
  6. Concurrent therapy exclusion: Rystiggo is not prescribed concurrently with Imaavy, Vyvgart, Vyvgart Hytrulo, Soliris, Bkemv, Epysqli, Ultomiris, Uplizna, or Zilbrysq.No concurrent listed therapy
  7. Dose and quantity: The member's current weight in kilograms is documented. If the request is for a dose increase, the new dose does not exceed both the applicable weight-based dose and one vial once weekly for the first 6 weeks of every 9-week cycle.420 mg if weight <50 kg; 560 mg if weight 50 to <100 kg; 840 mg if weight ≥100 kg; maximum 1 vial
  8. Rystiggo Quantity Limit
    Quantity limit1 vial
    ApplicationApplies to the Rystiggo dose within the policy quantity limits
    Revision detailQuantity limits were updated to 1 vial